ClinicalTrials.gg
RecruitingNCT07592325AS-TTUpdated May 18, 2026

Clinical Evaluation of the Access Socket Flexible Socket for Transtibial Prosthesis

An interventional study of Access Socket (AS) and Rigid Socket (RS) in Transtibial Amputation and Lower Limb Amputation Below Knee, sponsored by Union de Gestion des Etablissements des Caisses d'Assurance Maladie - Nord Est. Recruiting at 5 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by Union de Gestion des Etablissements des Caisses d'Assurance Maladie - Nord Est · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Transtibial amputation significantly impacts patient autonomy and quality of life, primarily due to the limitations of conventional rigid sockets, which restrict comfort and joint range of motion. The Access Socket (AS) is an innovative prosthetic socket combining a rigid carbon-fiber structure in key load-bearing areas with flexible urethane-resin (ProtheFLEX®) zones in regions typically rigid in conventional sockets. This hybrid design aims to improve comfort and pressure distribution while preserving the mechanical properties required for ambulation.

The AS has already demonstrated benefits in transfemoral amputees and is now reimbursed in France for that population. A preliminary uncontrolled study in 12 transtibial amputees suggested significant improvements in perceived function, comfort, satisfaction, and mobility.

This multicenter, randomized, open-label, two-arm crossover study aims to compare the (AS) with the standard rigid socket (RS) in 25 adults with transtibial amputation. Participants will wear each socket for approximately 4 weeks (after a 1-2 week adaptation period) in a randomized order. The primary outcome is the Patient Specific Functional Scale (PSFS). Secondary outcomes include comfort (SCS), satisfaction (OPUS), psychosocial adjustment (TAPES-R), mobility (PLUS-M), prosthesis utility (PEQ-U), and the proportion of patients electing to keep the AS at study completion.

Read the detailed description

Background. Lower-limb amputation affects more than 7,500 people annually in France, with approximately 50% at the transtibial level. The socket is the critical interface between the residual limb and the prosthesis, transmitting mechanical forces while needing to remain comfortable. Currently, only RS (carbon or resin) are listed on the French reimbursable products list (LPPR) for transtibial amputation. Documented limitations of rigid sockets include restricted knee flexion, walking discomfort in challenging environments, donning difficulties, and suboptimal pressure distribution that does not adapt to residual-limb volume changes.

Investigational device. The AS follows the same molding and shaping principles as the standard RS but differs in two manufacturing steps: (1) carbon fibers are placed only on lateral, postero-inferior, and inferior areas to provide structural rigidity; (2) stratification uses urethane resin (ProtheFLEX®, already used in medical-device manufacturing) instead of epoxy or acrylic resin, creating soft zones in regions typically rigid in conventional sockets.

Comparator. Both sockets are manufactured from the same plaster mold to ensure strictly identical internal geometry. Only the material structure (carbon/urethane distribution) differs; all other prosthetic components (intermediate piece, prosthetic foot) are identical.

Design rationale. A double-blind design is not feasible because participants can perceive differences in socket rigidity and prosthesis weight. The crossover design controls for between-subject variability and order effects.

Sample size. Based on the preliminary study (Patient Specific Functional Scale (PSFS) standard deviation 1.74), to detect a difference of 1.3 points (the PSFS MDC₉₀ for 3 items) with 80% power and α=0.05, 19 participants are required. 25 will be enrolled to account for dropouts and to provide a more representative sample for secondary endpoints.

Visits. Four study visits over approximately 14-21 weeks per participant: inclusion (V0), evaluation after first socket period (V1), evaluation after second socket period (V2), and an optional follow-up visit (V3) one month later if the participant elects to keep the AS.

02

Conditions studied

  • Transtibial Amputation
  • Lower Limb Amputation Below Knee

Keywords

  • Transtibial prosthesis
  • Prosthetic socket
  • Flexible socket
  • Access Socket
  • Comfort
  • Quality of life
  • Rehabilitation
  • cross over trial
  • Patient Specific Scale
03

In context

Lead sponsor

Union de Gestion des Etablissements des Caisses d'Assurance Maladie - Nord Est is the lead sponsor of 14 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Unilateral or bilateral transtibial amputation
  • Currently fitted with a definitive carbon rigid socket
  • Any residual-limb shape
  • Any etiology
  • Able to understand simple instructions, read, write, and provide - or able to be accompanied by a trusted person in case of inability to read/write autonomously
  • Provided free written informed consent
  • Aged 18 years or older
  • Affiliated to a social security system

Exclusion criteria

Exclusion Criteria:

  • Use of hydroalcoholic solution (HAS) for socket donning
  • Currently fitted with a provisional socket
  • Neurological pathology limiting capacity to participate in activities
  • Orthopedic pathology limiting capacity to participate in activities
  • Pregnant or breastfeeding women
  • Minors
  • Persons not under legal protection or unable to express consent
  • Persons under guardianship or curatorship
  • Persons under judicial protection
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Active comparator
    Group 1 (RS -> AS)

    Participants wear their standard rigid socket (RS) for 4 weeks, complete evaluation, then switch to the Access Socket (AS) for 1-2 weeks of adaptation followed by 4 weeks of wear, with a second evaluation.

    Device: Access Socket (AS) · Device: Rigid Socket (RS)

  • Active comparator
    Group 2 (AS -> RS)

    Participants receive the Access Socket (AS) first, with 1-2 weeks of adaptation followed by 4 weeks of wear and evaluation. They then switch to the standard rigid socket (RS) for 1-2 weeks of adaptation and 4 weeks of wear, with a second evaluation.

    Device: Access Socket (AS) · Device: Rigid Socket (RS)

Interventions

  • DeviceAccess Socket (AS)

    Hybrid prosthetic socket combining a rigid carbon-fiber structure in load-bearing areas (lateral, postero-inferior, inferior) with flexible urethane-resin (ProtheFLEX®) zones in regions typically rigid in conventional sockets. Manufactured from the same plaster mold as the rigid socket to ensure identical internal geometry.

  • DeviceRigid Socket (RS)

    Conventional definitive carbon-fiber rigid socket, currently the only socket type reimbursed in France for transtibial amputation (LPPR-listed). Standard of care comparator.

06

What researchers measure

Primary outcomes

  1. Patient Specific Functional Scale (PSFS) score

    Patient-centered self-report tool. The patient identifies 3-5 specific activities they have difficulty performing, then rates their ability on a 0-10 scale (0 = unable to perform, 10 = able to perform at pre-injury level). The final score is the mean of the ratings

    Time frame: One time at the end of each 4-week wear period (V1, V2 and V3)

Secondary outcomes

  1. Socket Comfort Scale (SCS) score

    0-10 numerical rating of socket comfort (0 = least comfortable imaginable, 10 = most comfortable imaginable)

    Time frame: One time at the end of each 4-week wear period (V1, V2 and V3)

  2. Orthotics Prosthetics Users Survey (OPUS) score

    Self-report instrument evaluating functional outcomes and quality of life specifically for orthosis and prosthesis users. Assesses lower-limb functional status, health-related quality of life, satisfaction with the device, and satisfaction with services. The higher the score, the more favorable the result for the device

    Time frame: One time at the end of each 4-week wear period (V1, V2 and V3)

  3. Trinity Amputation and Prosthesis Experience Scale - Revised (TAPES-R) score

    33-item multidimensional questionnaire evaluating psychosocial adjustment to amputation and prosthesis use, including general adjustment, social adjustment, activity restriction, and prosthesis satisfaction. The higher the global score, the more favorable the result for the device

    Time frame: One time at the end of each 4-week wear period (V1, V2 and V3)

  4. Prosthesis Evaluation Questionnaire - Utility subscale (PEQ-U) score

    The score is calculated as the mean of the 8 items in the subscale. Each item is rated on a Visual Analogue Scale (VAS) from 0 to 100. The total score ranges from 0 to 100, where higher scores indicate a better outcome (greater satisfaction and prosthesis utility)

    Time frame: One time at the end of each 4-week wear period (V1, V2 and V3)

  5. Proportion of participants electing to keep the Access Socket at study completion

    Percentage of participants who choose the AS over the RS at the end of the study, reported with 95% confidence interval. Participants are not informed of this option until the end of the study to avoid judgment bias

    Time frame: Through study completion, an average of 10 weeks

07

Study locations

5 of 5 sites recruiting
  • Hôpital National d'Instruction des Armées (HNIA) Percy
    Clamart, 92140, France
    Recruiting
  • Hôpital Filieris de Freyming-Merlebach
    Freyming-Merlebach, 57804, France
    Recruiting
  • CHU Grenoble Alpes - Hôpital Sud
    Grenoble, 38434, France
    Recruiting
    • Solène Maret, MD · Contactsmaret2@chu-grenoble.fr · +33 4 76 76 60 25
    • Solène MAret, MD · Principal investigator
    • Phillipe Escobar, MD · Sub investigator
  • Institut Régional de Médecine Physique et de Réadaptation (IRR) - Filière Locomoteur
    Nancy, 54000, France
    Recruiting
  • Insititution Nationale des Invalides
    Paris, 75007, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — : Individual participant data will not be shared. Aggregated study results will be published in scientific journals and a summary report will be transmitted to the CPP within 12 months of study completion

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Apr 2027, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2026
First posted
May 18, 2026
StartActual
Apr 27, 2026
Primary completionEst.
Apr 27, 2027
CompletionEst.
Oct 30, 2027
Last update
May 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07592325
Lead sponsor
Union de Gestion des Etablissements des Caisses d'Assurance Maladie - Nord Est
Collaborators
Institution Nationale des Invalides, Hôpital Filieris de Freyming-Merlebach, Ortho Access, H20 Orthopedie, Otto Bock France SNC, Hôpital d'Instruction des armées Percy, Clinical Investigation Center - University Hospital Grenoble
Responsible party
Sponsor
First posted
May 18, 2026
Start date
Apr 27, 2026
Primary completion
Apr 27, 2027 (estimated)
Completion
Oct 30, 2027 (estimated)
Last update
May 18, 2026

Study contacts

Isabelle Loiret, MD
Contact
isabelle.loiretpro@gmail.com
+33383529950
Isabelle Loiret, MD
principal investigator · Institut Régional de Médecine Physique et de Réadaptation (IRR), Nancy, France

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion